SkinBioTherapeutics Plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SBTX.L research report →
Companywww.skinbiotherapeutics.com
SkinBioTherapeutics plc, a life science company, engages in the research and development of technology that harnesses the human microbiome to improve health. The company develops SkinBiotix technology that can enhance the barrier effect of skin models, protect skin from infections, and repair wounds; and AxisBiotix that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets.
- CEO
- Rachel Lisa Parsonage
- IPO
- 2017
- Employees
- 15
- HQ
- Newcastle upon Tyne, GB
Price Chart
Valuation
- Market Cap
- $25.14M
- P/E
- -36.06
- P/S
- 5.42
- P/B
- 2.66
- EV/EBITDA
- -95.67
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 58.33%
- Op Margin
- -24.22%
- Net Margin
- -15.01%
- ROE
- -10.01%
- ROIC
- -10.05%
Growth & Income
- Revenue
- $4.64M · 283.63%
- Net Income
- $-696,253 · 75.79%
- EPS
- $-0.00 · 79.87%
- Op Income
- $-826,786
- FCF YoY
- 55.40%
Performance & Tape
- 52W High
- $23.00
- 52W Low
- $0.10
- 50D MA
- $4.18
- 200D MA
- $12.46
- Beta
- 0.13
- Avg Volume
- 1.40M
Get TickerSpark's AI analysis on SBTX.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our SBTX.L Coverage
We haven't published any research on SBTX.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SBTX.L Report →